|
1
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karaman B, Battal B, Sari S and Verim S:
Hepatocellular carcinoma review: Current treatment, and
evidence-based medicine. World J Gastroenterol. 20:18059–18060.
2014.PubMed/NCBI
|
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastro-enterology. 132:2557–2576. 2007. View Article : Google Scholar
|
|
4
|
Roberts LR: Sorafenib in liver cancer -
just the beginning. N Engl J Med. 359:420–422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosa A and Brivanlou AH: MicroRNAs in
early vertebrate development. Cell Cycle. 8:3513–3520. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang RM, Yang H, Fang F, Xu JF and Yang
LY: MicroRNA-331-3p promotes proliferation and metastasis of
hepatocellular carcinoma by targeting PH domain and leucine-rich
repeat protein phosphatase. Hepatology. 60:1251–1263. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Budhu A, Jia HL, Forgues M, Liu CG,
Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar
|
|
14
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar
|
|
15
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni
L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of
human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
|
|
16
|
Rani S, Gately K, Crown J, O'Byrne K and
O'Driscoll L: Global analysis of serum microRNAs as potential
biomarkers for lung adenocarcinoma. Cancer Biol Ther. 14:1104–1112.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma S, Chan YP, Kwan PS, Lee TK, Yan M,
Tang KH, Ling MT, Vielkind JR, Guan XY and Chan KW: MicroRNA-616
induces androgen-independent growth of prostate cancer cells by
suppressing expression of tissue factor pathway inhibitor TFPI-2.
Cancer Res. 71:583–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Książkiewicz M, Markiewicz A and Zaczek
AJ: Epithelial-mesenchymal transition: A hallmark in metastasis
formation linking circulating tumor cells and cancer stem cells.
Pathobiology. 79:195–208. 2012. View Article : Google Scholar
|
|
19
|
Reichl P, Haider C, Grubinger M and
Mikulits W: TGF-β in epithelial to mesenchymal transition and
metastasis of liver carcinoma. Curr Pharm Des. 18:4135–4147. 2012.
View Article : Google Scholar
|
|
20
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
23
|
Roberts LR and Gores GJ: Hepatocellular
carcinoma: Molecular pathways and new therapeutic targets. Semin
Liver Dis. 25:212–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, Brackett DJ, Roberts LR and Schmittgen TD: Association
of microRNA expression in hepatocellular carcinomas with hepatitis
infection, cirrhosis, and patient survival. Clin Cancer Res.
14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murakami Y, Yasuda T, Saigo K, Urashima T,
Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar
|
|
27
|
Haldrup C, Kosaka N, Ochiya T, Borre M,
Høyer S, Orntoft TF and Sorensen KD: Profiling of circulating
microRNAs for prostate cancer biomarker discovery. Drug Deliv
Transl Res. 4:19–30. 2014. View Article : Google Scholar
|
|
28
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi SS and Diehl AM:
Epithelial-to-mesenchymal transitions in the liver. Hepatology.
50:2007–2013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bullock MD, Sayan AE, Packham GK and
Mirnezami AH: MicroRNAs: Critical regulators of epithelial to
mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in
cancer progression. Biol Cell. 104:3–12. 2012. View Article : Google Scholar
|
|
31
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wan XW, Jiang M, Cao HF, He YQ, Liu SQ,
Qiu XH, Wu MC and Wang HY: The alteration of PTEN tumor suppressor
expression and its association with the histopathological features
of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol.
129:100–106. 2003.PubMed/NCBI
|
|
33
|
Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G,
Zeng Y, Sun B, Qian H, Chen L, et al: MicroRNA-21 suppresses PTEN
and hSulf-1 expression and promotes hepatocellular carcinoma
progression through AKT/ERK pathways. Cancer Lett. 337:226–236.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kong G, Zhang J, Zhang S, Shan C, Ye L and
Zhang X: Upregulated microRNA-29a by hepatitis B virus X protein
enhances hepatoma cell migration by targeting PTEN in cell culture
model. PLoS One. 6:e195182011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu W, Yang J, Feng X, Wang H, Ye S, Yang
P, Tan W, Wei G and Zhou Y: MicroRNA-32 (miR-32) regulates
phosphatase and tensin homologue (PTEN) expression and promotes
growth, migration, and invasion in colorectal carcinoma cells. Mol
Cancer. 12:302013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dasari VR, Kaur K, Velpula KK, Gujrati M,
Fassett D, Klopfenstein JD, Dinh DH and Rao JS: Upregulation of
PTEN in glioma cells by cord blood mesenchymal stem cells inhibits
migration via downregulation of the PI3K/Akt pathway. PLoS One.
5:e103502010. View Article : Google Scholar : PubMed/NCBI
|
